PROMPERÚ
21.4.2022 23:23:12 CEST | Business Wire | Press release
From April 5 to 7, Peru was represented in Berlin at the latest edition of Fruit Logistica 2022, the world's leading fresh fruit and vegetable fair, reports the Commission for the Promotion of Peru for Exports and Tourism (PROMPERÚ).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220416005003/en/
“This time around, Peru's business objective at Fruit Logistica will be to achieve 200 million USD in prospective business for the next 12 months and to generate 6,000 business contacts with the Peruvian delegation, in addition to consolidating a diversified and quality exportable supply,” stated the executive president of PROMPERÚ, Amora Carbajal.
“The sustainability of the Peruvian exportable supply will be a differentiating element at the fair. This is a focus that has been developing within our society and within the business models of Peruvian agro-export companies, improving their competitiveness and reducing environmental impacts through responsible water management, efficient carbon footprint management and fair trade strategies,” said the head of PROMPERÚ.
Fruit Logistica 2022 made it possible to consolidate the position of the Super Food Peru, Pisco, Spirit of Peru and Cafés del Perú brands. The commercial promotion campaign included activations and sampling of exotic fruits and specialty coffees in the national pavilion, in addition to pisco tastings, and typical regional dances.
The delegation led by PROMPERÚ was made up of the Ministry of Agriculture and Irrigation (MIDAGRI), Sierra and Selva Exportadora, Agro Ideas, the Embassy of Peru in Germany, directors of unions and the Association of Agricultural Producer Unions of Peru (AGAP).
Exports
Peruvian food sector exports to the European Union in 2021 reached 3,432 billion USD, growing by more than 13%. The main exports include fresh and dried avocados (604 million USD / +32.3%), unroasted coffee (422 million USD / +23.9%), fresh blueberries (360 million USD / +7.0%), fresh grapes (306 million USD / +28.3%), fresh mangoes (175 million USD / +0.7%), among other products.
In addition, foreign sales of fruit and vegetables amounted to 2,103 billion USD in this same period, with a growth of more than 17%, due to the notable performance of the Netherlands (1,132 billion USD / +19.6%), the United Kingdom (346 million USD / +9.4%), Spain (324 million USD / +22.5%) and Germany (56 million USD / +24.5%). These markets make up 95% of the value exported to the European Union.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220416005003/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release
Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release
The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter
Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release
Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom